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Objectives The purpose of this study was to determine the prevalence and prognostic role of left ventricular reverse remod-
eling (LVRR) in idiopathic dilated cardiomyopathy (IDCM).
Background Tailored medical therapy can lead to LVRR in IDCM. The prevalence and prognostic impact of LVRR remain unclear.
Methods We consecutively enrolled 361 IDCM patients. LVRR was defined as a left ventricular ejection fraction increase of
10 U or a left ventricular ejection fraction of 50% and a decrease in indexed left ventricular end-diastolic diameter
of 10% or indexed left ventricular end-diastolic diameter of 33 mm/m2 at 24 months (range 9 to 36 months).
Follow-up echocardiographic data were available for 242 patients (67%), 34 (9%) died/underwent heart transplanta-
tion (HTx) before re-evaluation, and 85 (24%) did not have a complete re-evaluation. After re-evaluation, the surviving
patients were followed for 110  53 months; there were 55 deaths (23%) and 32 HTx (13%).
Results LVRR was found in 89 of 242 patients (37%). Baseline predictors of LVRR were higher systolic blood pressure
(p  0.047) and the absence of left bundle branch block (p  0.009). When added to a prognostic baseline
model including male sex, heart failure duration, New York Heart Association functional classes III to IV, LVEF,
significant mitral regurgitation, and beta-blockers, LVRR, New York Heart Association functional classes III to IV,
and significant mitral regurgitation after 24 months emerged as independent predictors of death/HTx and heart
failure death/HTx. The model including follow-up variables showed additional prognostic power with respect to
baseline model (for death/HTx, area under the curve: 0.80 vs. 0.70, respectively, p  0.004). Furthermore, only
LVRR was significantly associated with sudden death/major ventricular arrhythmia in the long-term.
Conclusions LVRR characterized approximately one-third of IDCM patients surviving 2 years while receiving optimal medical
therapy and allowed a more accurate long-term prognostic stratification of the disease. (J Am Coll Cardiol
2011;57:1468–76) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.11.030Dilated cardiomyopathy is a myocardial disease character-
ized by left ventricular dilation and systolic dysfunction that
commonly result in heart failure (HF) (1,2). In the majority
of patients, an etiological basis cannot be identified, and the
patient is referred to as having an idiopathic dilated cardio-
myopathy (IDCM) (3,4). IDCM has an incidence of36.5
cases per 100,000 persons (5), and it accounts for nearly
50,000 hospitalizations and 10,000 deaths each year in the
United States (6). The long-term prognosis of the disease
has improved remarkably during the past 20 years (7,8).
From the *Cardiovascular Department, “Ospedali Riuniti” and University of Trieste,
Trieste, Italy; †Department of Environmental Medicine and Public Health, Univer-
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relationships to disclose.Manuscript received September 13, 2010; revised manuscript received November 8,
2010; accepted November 9, 2010.However, despite recent and continuous progress in drug
treatment and, where applicable, cardiac resynchronization
therapy (CRT), IDCM still remains the most common reason
for heart transplantation (HTx) in adults and children (9,10).
See page 1477
Cardiac remodeling can be defined as genome expression,
molecular, cellular, and interstitial changes that are mani-
fested clinically as changes in size, shape, and function of
the heart after cardiac injury (4,11). This phenomenon
characterizes the natural history of IDCM (4,7,8). Further-
more, several authors over the past decade have suggested
that in some IDCM patients, particularly those receiving
tailored neurohormonal medical treatment (12–17), the left
ventricle could undergo a reverse remodeling (left ventricu-
lar reverse remodeling [LVRR]), characterized by a decrease
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with a significant improvement of pump function. Identifi-
cation of LVRR could potentially add prognostic value for
the stratification of long-term risk, whether or not associ-
ated with an improvement of symptoms. Nevertheless, there
are no studies focused on early identification of clinical
characteristics of this particular subgroup of IDCM patients
in the literature and in particular the impact of early
diagnosis and pharmacological treatment on LVRR and its
long-term prognostic role.
Therefore, the objectives of the present study were to
determine the prevalence of LVRR in IDCM patients
receiving tailored medical therapy and to assess the clinical
and laboratory predictors of LVRR and its prognostic role
in long-term follow-up.
Methods
Study population. From 1988 to 1997, 361 consecutive
patients with IDCM were enrolled in this study; they are
part of the Heart Muscle Disease Registry of Trieste, a
database of a tertiary referral center on cardiomyopathies.
The end of follow-up was considered to be December 31,
2007, the date of death, or HTx. This study population had
a potential clinical follow-up of at least 10 years. An IDCM
diagnosis was defined according to the World Health
Organization criteria (1). Informed consent was obtained
from all subjects under the institutional review board poli-
cies of the Trieste hospital administration.
At enrollment, after obtaining an accurate clinical history,
all patients underwent a physical examination, blood sam-
pling for laboratory tests, 12-lead electrocardiography, stan-
dard chest X-ray, 24-h Holter monitoring, a complete
echocardiographic and Doppler evaluation, exercise testing,
and coronary angiography.
Until 1996, patients routinely underwent endomyocardial
biopsy to exclude active myocarditis (according to the Dallas
criteria) (18). Thereafter, a biopsy was performed only on
patients with recent-onset HF and/or a clinical history
suggesting active myocarditis.
The patients underwent a structured follow-up evaluation
at the Cardiomyopathy Clinic of the Cardiovascular De-
partment of Trieste. For the purpose of the study, we
analyzed 242 of 361 patients (67%) with available clinical
and echocardiographic data at baseline evaluation and at
mid-term follow-up (mean 24  7 months, range 9 to 36
months) receiving tailored medical treatment.
Regarding treatment, following our protocol, all patients
enrolled in our study were treated with beta-blockers (meto-
prolol tartrate and later carvedilol) where appropriate, al-
ways following careful clinical stabilization on the optimal
dose of angiotensin-converting enzyme (ACE) inhibitors,
in addition to digitalis and diuretics, as clinically indicated.
Daily doses of ACE inhibitors and beta-blockers are re-
ported as equivalent of enalapril and carvedilol, respectively
(enalapril equivalent doses: captopril, 7.5; lisinopril, 1; carve- idilol equivalent doses: metoprolol,
2) (19) and refer to the end of
titration period (generally 1 to 3
months after enrollment).
Moreover, from 1998 onward,
after the preliminary data from our
registry and the results of some
trials on secondary prevention of
sudden death (SD) (20–22), the
use of an implantable cardioverter-
defibrillator (ICD) for primary
prevention began to take place in
IDCM patients matching high-
risk criteria for SD (persistent
left ventricular ejection fraction
[LVEF]) 35% and New York
Heart Association functional
classes II to III despite long-term
optimal treatment) (23–25). No
CRT was used in our population
at mid-term follow-up.
Echocardiographic study. Con-
ventional M-mode, 2-dimensional,
and Doppler variables were mea-
sured in all patients according to
international guidelines. Left ventricular diameters were mea-
sured at M-mode and volumes, and LVEFs were calculated at
2-dimensional echocardiography from an apical 4-chamber
view using the biplane method of disks. Right ventricular
areas and fractional area contraction, as well as the end-
systolic left atrial area, were also measured using the same
approach. Mitral regurgitation was semiquantitatively graded
considering the regurgitant jet area at color Doppler imaging
(26). Mitral regurgitation with jet area4 cm2 was considered
significant. The transmitral flow velocity curve was obtained by
pulsed Doppler imaging, positioning the sample volume be-
tween the tips of the mitral leaflets. E- and A-wave peak
velocities, E-wave deceleration time, and the ratio of early
transmitral flow velocity to atrial flow velocity were measured,
as described previously (20,26). The left ventricular filling
pattern was classified as restrictive in the presence of an E-wave
deceleration time 120 ms or a ratio of early transmitral flow
elocity to atrial flow velocity 2 associated with an E-wave
eceleration time 150 ms (27); for patients in atrial fibrilla-
ion, only E-wave data were considered.
All measurements were obtained from the mean of 3
eats for the patients with sinus rhythm, and 5 beats for
hose with atrial fibrillation. Chamber diameters, areas, and
olumes were normalized for body surface area.
Reproducibility of Doppler echocardiographic data was
reviously published by our group (28).
tudy design. LVRR was defined as the combined pres-
nce at mid-term follow-up of: 1) an increase in LVEF of at
east 10 points or a follow-up LVEF50% (in patients with
n LVEF of 45% to 49% at enrollment); and 2) a decrease
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
CRT  cardiac
resynchronization therapy
HF  heart failure
HTx  heart
transplantation
ICD  implantable
cardioverter-defibrillator
IDCM  idiopathic dilated
cardiomyopathy
LBBB  left bundle branch
block
LVEF  left ventricular
ejection fraction
LVRR  left ventricular
reverse remodeling
MVA  major ventricular
arrhythmia
NYHA  New York Heart
Association
SD  sudden deathn indexed left ventricular end-diastolic diameter of at least
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33 mm/m2 (29).
The primary prognostic end point was considered death
or HTx. The indication for HTx was considered in patients
with refractory HF requiring inotropic treatment and/or
mechanical support (status I) (30).
Two secondary combined clinical end points were con-
sidered: 1) HF death/HTx and 2) SD and major ventricular
arrhythmias (MVAs). SD was defined as an immediate
death or a death occurring within 1 h after the onset of
symptoms or during sleep in stable NYHA functional class
I to III patients. As MVAs were considered ventricular
fibrillation/flutter or a sustained ventricular tachycardia
(hemodynamically unstable or lasting more than 30 s) or
appropriate ICD intervention.
Information regarding the end points was obtained di-
rectly from the patient, from his or her physician, or from
the registers of death of the municipalities of residence. This
study was performed in accordance with the guidelines set
by the Declaration of Helsinki (31) and with the local legal
requirements.
Statistical analysis. All values are reported as mean  SD
or percentages. Continuous variables were compared be-
tween groups by analysis of variance, whereas for binary
variables, the chi-square test was used by applying Yates
correction for continuity when necessary. To predict LVRR
from baseline variables, first a univariate screening of all
clinical-laboratory parameters of patients at enrollment was
made (estimating univariable logistic regression models
variable by variable); then to estimate the multivariable
logistic regression equation, a stepwise backward condi-
tional algorithm was applied to the list of selected param-
eters (i.e., with p  0.1) at the univariate procedure.
Survival curves were calculated according to the Kaplan-
Meier method, and the comparison between curves was
Figure 1 Follow-Up of Idiopathic Dilated Cardiomyopathy Study
HTx  heart transplantation; mo  months; pts  patients.carried out with the log-rank test.Two prognostic survival models were compared by
means of the Cox hazard proportional analysis: model 1,
which included clinical-laboratory data at baseline eval-
uation (male sex, HF duration, NYHA functional classes
III to IV, LVEF, moderate to severe mitral regurgitation,
treatment with beta-blockers), selected by means of a
backward conditional stepwise procedure, and model 2,
which also incorporated the presence of LVRR, NYHA
functional classes III to IV, and moderate to severe mitral
regurgitation at mid-term follow-up. The prognostic
accuracy of the 2 models and the possible additive
prognostic role of the model 2 with respect to the sole
model 1 were evaluated by using receiver-operating
characteristic analysis.
All results were considered statistically significant
when p  0.05. The entire analysis was performed using
the SPSS package, version 14.0 (SPSS Inc., Chicago,
Illinois) and R statistical software version 2.5 (32).
Results
Clinical and echocardiographic data were available for 242
of 361 patients (67%) at mid-term follow-up (24  7
months, range 9 to 36 months) (Fig. 1). After the mid-term
evaluation, the surviving patients were followed for a mean
follow-up of 110 53 months; there were 55 deaths and 32
HTx.
The clinical and laboratory findings of these patients at
the first evaluation are summarized in Table 1. Our patients
were predominantly males (74%). The mean age at diagno-
sis was 43  13 years. A family pattern was identified in
26% of cases. HF duration before diagnosis was 13  25
months. Less than one-fourth of our population belonged to
NYHA functional classes III to IV at baseline (18%). The
electrocardiogram showed a complete left bundle branch
lationPopublock (LBBB) in 32% of patients. The echocardiographic
a
v
s
p
c
L
p
e
1471JACC Vol. 57, No. 13, 2011 Merlo et al.
March 29, 2011:1468–76 Reverse Remodeling in Dilated Cardiomyopathyevaluation at baseline was consistent with a severe reduction
of systolic function (LVEF 31  10%) and with a moderate
left ventricular dilation (indexed end-diastolic diameter:
37  5 mm/m2). A restrictive filling pattern was found in
24% of our population, and significant mitral regurgitation
in 34%. Neurohormonal drug treatment with ACE inhib-
itors and beta-blockers was tailored in the majority of
patients (91% and 85%, respectively) at target doses.
Eighty-five patients (24%) had not undergone a complete
noninvasive evaluation at mid-term follow-up. Most of
clinical-laboratory features of this group of patients, includ-
ing left ventricular shape, were not different from those of
the study population, except that they were older with
relatively higher blood pressure and more frequent atrial
fibrillation (Table 2). Initially, they were less intensively
treated with beta-blockers, and then they were followed at
other centers. The long-term survival curves were not
different from those of the study population (data not
shown).
Thirty-four patients (9%) achieved the primary end point
(death/HTx) before this follow-up visit (7 [2%] HF deaths;
15 [4%] urgent HTx; 11 [3%] SD). As expected, patients
Baseline Characteristics of theStudy Popul tion (n  242)Table 1 B seli e Charact ristics of theStudy Population (n  242)
Age, yrs 43 13
Males 74
Familial IDCM 26
Duration of HF, months 13 25
SBP, mm Hg 124 14
DBP, mm Hg 79 10
NYHA functional class III to IV 18
Serum hemoglobin, g/dl 14 1.5
Serum creatinine, mg/dl 1.1 0.2
Sinus rhythm 94
LBBB 32
LVEF, % 31 10
LVEF 30% 50
LVEDDI, mm/m2 37 5
LVESDI, mm/m2 31 6
LVEDVI, ml/m2 106 39
LVESVI, ml/m2 75 35
Restrictive filling pattern 24
Significant MR 34
Beta-blockers 85
Carvedilol equivalent dose, mg/day 57 25
ACE inhibitors/sartans 91
Enalapril equivalent dose, mg/day 22 12
Diuretics 53
Digitalis 78
Amiodarone 23
Values are mean  SD or %.
ACE angiotensin-converting enzyme; DBP diastolic blood pressure; HF heart failure; IDCM
idiopathic dilated cardiomyopathy; LBBB  left bundle branch block; LVEDDI  left ventricular
nd-diastolic diameter index; LVEDVI  left ventricular end-diastolic volume index; LVEF  left
ventricular ejection fraction; LVESDI  left ventricular end-systolic diameter index; LVESVI  left
ventricular end-systolic volume index; MR  mitral regurgitation; NYHA  New York Heart
Association; SBP  systolic blood pressure.who achieved the primary end point were characterized at abaseline by more severe and advanced disease with respect to
the remaining patients (data not shown).
At mid-term follow-up, LVRR was found in 89 of 242
patients analyzed (37%). At baseline, patients with LVRR
showed lower LVEF (28  8% vs. 33  8%, p  0.001) and
higher rate of a left ventricular restrictive filling pattern (42%
s. 15%, p  0.004) with respect to the others. No other
ignificant differences were documented (data not shown).
At logistic regression analysis (Table 3), baseline systolic blood
ressure (for every 10-mm Hg increase: odds ratio: 1.23, 95%
onfidence interval: 1.01 to 1.53; p  0.047) and the absence of
BBB (odds ratio: 2.47, 95% confidence interval: 1.25 to 4.87;
 0.009) resulted as independent predictors of LVRR (univar-
iate odds ratios are reported in Online Table 1).
The survival curves of the study population classified
according to LVRR are shown in Figure 2. IDCM patients
with LVRR had a significantly better long-term prognosis
with respect to the others (p  0.001). The HTx-free
survival rates were, respectively, 94%, 85%, and 78% versus
Comparison of Baseline Clinical-LaboratoryFeatures Between Study Population andPatient With Incompl te Noninv siveR -Ev luation at Mid-T rm Follow-Up
Table 2
Comparison of Baseline Clinical-Laboratory
Features Between Study Population and
Patients With Incomplete Noninvasive
Re-Evaluation at Mid-Term Follow-Up
Noninvasive Re-Evaluation
p Value
Incomplete
(n  85)
Complete
(n  242)
Age, yrs 49 14 43 13 0.002
Male 70 74 NS
HF duration, months 12 21 13 25 NS
Familial IDCM 21 26 NS
SBP, mm Hg 129 18 124 14 0.008
NYHA functional class III to IV 20 18 NS
GFR 60 ml/min 17 11 NS
Sinus rhythm 86 94 0.022
LBBB 33 32 NS
LVEF, % 31 7 31 10 NS
LVEDDI, mm/m2 36 5 37 5 NS
LVEDVI, ml/m2 101 37 106 39 NS
Restrictive filling pattern 25 24 NS
Significant MR 39 34 NS
ACE inhibitors/sartans 93 91 NS
Beta-blockers 68 85 0.001
Diuretics 61 53 NS
Digitalis 79 78 NS
Values are mean  SD or %.
GFR  glomerular filtration rate; other abbreviations as in Table 1.
Baseline Independent Predictorsof LVRR at Mid-Term Follow-UpTable 3 Baseline Ind pendent Predictorsof LVRR at Mid-Term Follow-Up
OR 95% CI p Value
SBP, per 10-mm
Hg increase
1.23 1.01–1.53 0.047
Absence of LBBB 2.47 1.25–4.87 0.009CI  confidence interval; LVRR  left ventricular reverse remodeling; OR  odds ratio; other
bbreviations as in Table 1.
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patients with and without LVRR.
The event rates of the patients with LVRR with respect
to the other patients are shown in Table 4. LVRR proved to
be associated with a lower rate of HF death/HTx (6% vs.
27%, p  0.005), and SD/MVA (16% vs. 29%, p  0.022).
Baseline prognostic independent predictors (model 1) for
death/HTx, HF death/HTx, and SD/MVA are shown in
Table 5 (univariate hazard ratios are reported in Online
Table 2). Table 6 shows the prognostic role of model 1 and
odel 2 (which included LVRR, NYHA functional classes III
o IV and moderate to severe mitral regurgitation at mid-term
ollow-up) both for predicting primary and secondary end
oints. LVRR resulted significantly predictive for HTx-free
urvival (hazard ratio: 0.44, 95% confidence interval: 0.25 to
.78; p  0.005), independently from other follow-up param-
ters. Similar results were also obtained with this model for
rediction of the secondary end points, differently from
YHA functional classes III to IV and moderate to severe
Figure 2 Long-Term Prognostic Impact of LVRR in
Idiopathic Dilated Cardiomyopathy Patients
Comparison of long-term heart transplantation (HTx)-free survival curves
between left ventricular reverse remodeling (LVRR) and non-LVRR patient sub-
groups. Note that the starting time point is 24 months (range 9 to 36 months).
D  death.
Events in the Patients With LVRR at Mid-Term FCompared With th Other Patients on Long-TermTable 4 Events in the With LVRR aCompared With the Other Patients
Type of Event
All Patients
n  242
Overall death/HTx 87 (36)
Cardiovascular death 51 (21)
HF death/HTx 47 (19)
Sudden death/MVA 58 (24)Values are n (%). *Long-term follow up was 123  61 months.
HTx  heart transplantation; MVA  major ventricular arrhythmia; other aitral regurgitation at mid-term follow-up that were not
rotective against SD/MVA in the long term.
The accuracy comparison between the 2 models is shown in
he receiver-operating characteristic curves (Fig. 3). The incre-
ental prognostic power of model 2 versus model 1 is
emonstrated both for death/HTx (area under the curve: 0.80
s. 0.70, respectively; p 0.004) and for HF death/HTx (area
nder the curve: 0.77 vs. 0.68, respectively; p 0.002). A trend
oward statistical significance was shown also for SD/MVA
area under the curve: 0.69 vs. 0.63, respectively; p  0.1).
imilar results were obtained by repeating the analysis, censor-
ng heart transplant recipients (data not shown).
iscussion
he first main result of the present study is the observation
hat about one-third of our patients with IDCM surviving
years showed an LVRR at mid-term follow-up on tailored
edical therapy. To the best of our knowledge, this is the
rst study that analyzes LVRR in a large population of
atients with IDCM enrolled in a tertiary center and
ollowed for at least 10 years. On the other hand, our data
re in keeping with those in the literature concerning HF in
eneral, showing that treatment with drugs capable of
-Uplow-Up*-Term Follow-Up
ng-Term Follow-Up*
RR
9 (37%)
No LVRR
n  153 (63%) p Value
(19) 70 (46) 0.001
(10) 42 (27) 0.001
(6) 42 (27) 0.005
(16) 44 (29) 0.022
Baseline Prognostic Model (Model 1)Table 5 Baseline Prognostic Model (Model 1)
HR 95% CI p Value AUC
Death/HTx
Male 1.72 1.11–2.64 0.01
0.70
HF duration (per 12-month
increase)
1.13 1.05–1.21 0.001
NYHA functional class III to IV 1.68 1.12–2.50 0.01
LVEF (per 10-U decrease) 1.35 1.11–1.64 0.002
Moderate to severe MR 1.52 1.04–2.23 0.03
Beta-blockers 0.46 0.31–0.68 0.001
Pump failure death/HTx
HF duration (per 12-month
increase)
1.12 1.02–1.23 0.01
0.68NYHA functional class III to IV 1.78 1.00–3.19 0.05
Moderate to severe MR 2.51 1.37–4.59 0.003
Beta-blockers 0.44 0.25–0.77 0.004
Sudden death/MVA
HF duration (per 12-month
increase)
1.11 1.01–1.22 0.03
0.63
LVEF (per 10-U decrease) 1.49 1.22–1.81 0.005
AUC  area under the curve; HR  hazard ratio; other abbreviations as in Tables 1, 3, and 4.ollowF lt Mid
on Lo
LV
n  8
17
9
5
14bbreviations as in Tables 1 and 3.
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in patients with chronic HF and depressed LVEF secondary
to multiple etiologies (12–17,33–35). Several hypotheses
about the potential mechanisms of LVRR induced by drug
therapy were postulated. First, the treatment of HF can
influence the hemodynamics favorably by decreasing left
ventricular pre-load and afterload. Moreover, recent studies
have also suggested a direct action of beta-blockers on
cardiac myocytes. In fact, patients with improvement of the
LVEF with beta-blocker treatment were characterized by a
concurrent increase in sarcoplasmic reticulum Ca2 ATPase
mRNA and alpha-myosin heavy chain mRNA, thus sug-
gesting that left ventricular functional improvement was
associated with favorable changes in myocardial gene ex-
pression (34).
In our study, a higher baseline systolic blood pressure and
a lower prevalence of LBBB turned out to be independent
predictors of LVRR. This may suggest a higher probability
of improvement in patients with more chances of tailoring
treatment and an increased possibility of modulating the
afterload in the absence of severe, long-standing, irreversible
structural abnormalities (7,8). This fact confirms the impor-
tance of an early diagnosis of the disease to achieve the
maximum benefit from tailored neurohormonal treatment
in terms of HF deaths/HTx and MVA prevention. How-
ever, it must be noted that LVRR could not be obtained in
Incremental Prognostic Role of LVRR,NYHA Functional Classes III to IV,and Moderate to Sever MR atMi -Term Follow-Up (Mode 2)
Table 6
Incremental Prognostic Role of LVRR,
NYHA Functional Classes III to IV,
and Moderate to Severe MR at
Mid-Term Follow-Up (Model 2)
HR 95% CI p Value AUC
Death/HTx 0.80
Model 1* 2.02 1.48–2.76 0.001
LVRR 0.44 0.25–0.78 0.005
NYHA functional class III to IV
at 24 months
3.75 2.03–6.95 0.001
Moderate to severe MR
at 24 months
1.70 1.02–2.83 0.04
Pump failure death/HTx 0.77
Model 1† 1.82 1.04–3.17 0.03
LVRR 0.24 0.07–0.84 0.03
NYHA functional class III to IV
at 24 months
6.73 2.92–15.53 0.001
Moderate to severe MR
at 24 months
2.79 1.22–6.34 0.01
Sudden death/MVA 0.69
Model 1‡ 2.18 1.49–3.19 0.001
LVRR 0.39 0.21–0.74 0.004
NYHA functional class III to IV
at 24 months
1.13 0.41–3.12 0.80
Moderate to severe MR
at 24 months
1.50 0.80–2.79 0.20
*Model 1 includes baseline variables: male sex, HF duration, NYHA functional classes III to IV, LVEF,
moderate to severe MR, and beta-blockers. †Model 1 includes baseline variables: HF duration,
NYHA functional classes III to IV, moderate to severe MR, and beta-blockers. ‡Model 1 includes
baseline variables: HF duration, and LVEF.
Abbreviations as in Tables 1, 3, 4, and 5.every single patient, and some patients died or underwentFigure 3 ROC Curves to Evaluate Accuracy
of Model 2 Versus Model 1
Comparison of the receiver-operating characteristic (ROC) curves for prediction
of events between the baseline model (model 1, dashed line) and the model
containing left ventricular reverse remodeling, New York Heart Association func-
tional class, and mitral regurgitation at mid-term follow-up (model 2, solid line).
A significant improvement in accuracy is observed for model 2 in predicting
death/heart transplantation (HTx) and pump failure death/HTx; a nonsignificant
trend was observed for prediction of sudden death/major ventricular arrhythmia
(MVA). AUC  area under the curve.
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subgroup presented a severe and advanced disease at diag-
nosis and needed early aggressive therapeutic therapy. Thus,
the need emerges for very early identification of IDCM
patients with a poor short-term prognosis to apply nonphar-
macological therapies as soon as possible.
Long-term prognostic implications of LVRR. In our
patients with IDCM, the evolution of LVRR at mid-term
follow-up receiving tailored medical treatment predicted a
lower rate of major (HTx is not a fatal event) cardiovascular
events on long-term follow-up, independently from NYHA
functional class and mitral regurgitation during follow-up. In
fact, differently from NYHA functional classes III to IV and
moderate to severe mitral regurgitation at mid-term follow-up,
LVRR showed a significant independent protective prognostic
role for death/HTx, HF death/HTX, and SD/MVA. On the
other hand, NYHA functional classes III to IV and significant
mitral regurgitation showed an independent prognostic role for
death/HTx and HF death/HTx but not for SD/MVA.
As far as we know, there are no other studies reported in
literature that evaluated the association between LVRR and
major cardiovascular events in the long term in a large
cohort of IDCM patients exclusively receiving tailored
medical treatment. In a recent study, Yu et al. (36) showed
a significant improvement in the survival rate of HF patients
with LVRR; however, in that study, these results were
achieved by CRT treatment, and the follow-up was rela-
tively short (approximately 2 years).
Our data also demonstrated the improved accuracy of the
prognostic model containing combined baseline and mid-
term follow-up data, a key issue in the long-term manage-
ment of IDCM. This underscores the importance not only
of an accurate and complete initial diagnosis, but also of
continuous, individualized follow-up with quantitative
echocardiographic assessment and tailored drug treatment
based on well-established clinical and laboratory data.
Clinical implications. This study underscores that about
one-third of patients with IDCM shows a mid-term signifi-
cant improvement of symptoms and LVRR on optimal tai-
lored medical therapy. This group of patients had a favorable
prognosis and was characterized at diagnosis by reversible
myocardial damage despite severe hemodynamic impairment
(LVRR patients presented a lower baseline LVEF and higher
rate of a left ventricular restrictive filling pattern with respect to
the others) and could tolerate a higher dose of ACE inhibitors
and beta-blockers (LVRR group vs. others at 24 months,
respectively: equivalent dose of enalapril 30  13 mg/day vs.
24  13 mg/day, p  0.001; equivalent dose of carvedilol
73  29 mg/day vs. 62  33 mg/day, p  0.018). This result
ighlights that, using LVRR, we could early identify a sub-
roup of patients with a benign prognosis among a population
ith a severe form of the disease.
Although the improvement of symptoms is already ex-
ressed after few months, reverse remodeling usually begins
fter 6 months, to be completed in 12 to 24 months. As a
onsequence, patients who express LVRR do not match anymore class I indications for ICD or CRT implantation show-
ing a long-term lower risk of major ventricular arrhythmias
(37). However, some patients die earlier during the follow-up,
sometimes suddenly. The timing of ICD and/or CRT implan-
tation in IDCM is a critical issue. Although the guidelines
suggest that an ICD can be indicated only in patients who are
already receiving maximal medical therapy, it is not clear how
the optimization of treatment can modify ICD indications and
how safe it is to wait to optimize treatment before implanting
an ICD. Patients with more advanced disease at diagnosis (the
presence of LBBB, low systolic blood pressure), usually treated
with a lower dose of ACE inhibitors and beta-blockers, with
no significant improvement of symptoms and hemodynamics
within 3 to 6 months, are associated with a lower probability of
LVRR after 12 to 24 months and a higher risk of cardiovas-
cular events, including sudden death. In these cases, it probably
would not be safe to wait further without ICD/CRT implan-
tation. Nevertheless, there is the need for further studies to
recognize the patients in which early implantation of ICD
and/or CRT are indicated.
LVRR was the unique follow-up parameter indepen-
dently associated with SD/MVA in the long term. The
improvement of HF symptoms and of mitral regurgitation
emerged as predictors only for death/HTx and HF death/
HTx. The present study underscores the importance not
only of an accurate and complete initial diagnosis, but also
of continuous, individualized follow-up on tailored drug
treatment with quantitative echocardiographic assessment
based on well-established clinical and laboratory data. From
our results, there is not only a clear prognostic value of the
complete left ventricular contractility and dimension resto-
ration, but also a role for progressive improvement of left
ventricular dysfunction and dilation during the mid-term
follow-up for all the major cardiovascular events related to
IDCM. Using LVRR, we could describe at the same time
the dynamic process of clinical-laboratory improvement of
IDCM patients receiving optimal medical treatment and
the achievement of a target absolute value of LVEF. This
issue represents a new finding that could be of great interest
for the clinical cardiology community.
Finally, despite significant improvement of left ventricu-
lar function and remodeling at mid-term, long-term evolu-
tion of IDCM is actually not known. Because the possibility
of long-term progressive remodeling also in patients with
initial recovery of left ventricular function (38), continuous
surveillance over time of the evolution of IDCM is therefore
mandatory to identify those at higher risk and the correct
timing of nonpharmacological interventions.
Study limitations. The current study population was en-
rolled in a tertiary referral center for cardiomyopathies and
HF, thus imposing a selection bias with respect to the
characteristics of IDCM in the general population.
In addition, 85 of the initial 361 patients did not have a
complete noninvasive evaluation (including valuable echo-
cardiographic data), decreasing the number of potential
controls for analysis. Even if this group of patients had
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were older with relatively higher blood pressure and more
frequent atrial fibrillation) and similar long-term outcome
compared with the study population, our prognostic models
were obtained in patients with complete follow-up data and
treated according to current evidence (i.e., with ACE
inhibitors and beta-blockers in 90% of them) and should be
applied only to this type of patient.
Furthermore, 34 of 361 patients (9%) died or underwent
HTx before re-evaluation. We excluded these patients from
our analysis because no complete clinical-laboratory data
were available to classify them as non-LVRR; moreover, 11
of them died suddenly. This issue underscores the need for
prognostic predictors of LVRR to apply early aggressive
therapies (HTx, ICD, and/or CRT) in patients with an
advanced and severe disease already at diagnosis. In the
present study, LVRR was assessed by the combined pres-
ence at mid-term follow-up of a decrease in left ventricular
dimensions and increase in LVEF.
Finally, we must note that despite the stepwise procedure
used to find the most significant set of independent prognostic
factors, in the case of the cause-specific end points of HF
death/HTX and SD/MVA, an overfitting issue could be
present because Cox models should be used with a minimum
of 5 to 10 outcome events per predictor variable (39).
Conclusions
LVRR characterized about one-third of our IDCM popula-
tion, alive at mid-term follow-up receiving tailored pharmaco-
logical treatment, and emerged as an independent predictor of
long-term prognosis. The evolution to LVRR suggests less
structural cardiac damage at the time of diagnosis and a higher
probability of better response to treatment. Our study under-
scores the importance of considering clinical and laboratory
data at baseline and during follow-up to improve the prognos-
tic stratification of IDCM.
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